SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

NCT07470840 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER_GOV

Sponsor class

Conditions

Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions

RADIATION: Stereotactic Body Radiation Therapy (SBRT)
DRUG: Anlotinib
DRUG: Bemarituzumab

Sponsor

Fujian Cancer Hospital